stem cell trial result out, page-29

Jeckel from the ann 7/4/2014
..... There is only one approved compound in the US, Novantrone®, for use in secondary (chronic) progressive MS which can only be used for two to three years because of safety limitations.
The patent also claims all desired doses of ATL1102 for use in these treatments including those described in the pharmacometric modeling2 for dosing in the next clinical trial being a six month Phase IIb study. The modelling recommended doses that on a cumulative basis are equivalent to those tested in the recent toxicology study. ANP announced to the ASX on 1st April 2014, major findings from an ATL1102 chronic monkey study and plans to meet with the FDA in Q3’2014 at a proposed pre- Investigational New Drug meeting regarding the study design for a Phase IIb MS trial. The Company expects these interactions with the FDA to run in parallel to those with potential pharmaceutical partners. "

There is only one other compound used for PMS and its what makes this patent so exciting now we know 100% that we are moving forward. Not so exciting is the way in which this has been relayed to market but if you can see through all the crapola we have an Ms drug going to the Fda and every possibility it will be with a partner.